Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effects of reperfusion grade and reperfusion strategy on the clinical outcome: Insights from ESCAPE-NA1 trial

P. Cimflova, JM. Ospel, N. Singh, M. Marko, N. Kashani, A. Mayank, A. Demchuk, B. Menon, AY. Poppe, R. Nogueira, R. McTaggart, JL. Rempel, M. Tymianski, MD. Hill, MA. Almekhlafi, M. Goyal

. 2024 ; 30 (6) : 804-811. [pub] 20241014

Language English Country United States

Document type Journal Article, Randomized Controlled Trial, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25003223
E-resources Online Full text

NLK Free Medical Journals from 2008 to 1 year ago
PubMed Central from 1999 to 1 year ago
Europe PubMed Central from 1999 to 1 year ago

Links

PubMed 39397754
DOI 10.1177/15910199241288874
Knihovny.cz E-resources

BACKGROUND: We evaluated the association of reperfusion quality and different patterns of achieved reperfusion with clinical and radiological outcomes in the ESCAPE NA1 trial. METHODS: Data are from the ESCAPE-NA1 trial. Good clinical outcome [90-day modified Rankin Scale (mRS) 0-2], excellent outcome (90-day mRS0-1), isolated subarachnoid hemorrhage, symptomatic hemorrhage (sICH) on follow-up imaging, and death were compared across different levels of reperfusion defined by expanded Treatment in Cerebral Infarction (eTICI) Scale. Comparisons were also made between patients with (a) first-pass eTICI 2c3 reperfusion vs multiple-pass eTICI 2c3; (b) final eTICI 2b reperfusion vs eTICI 2b converted-to-eTICI 2c3; (c) sudden reperfusion vs gradual reperfusion if >1 pass was required. Multivariable logistic regression was used to test associations of reperfusion grade and clinical outcomes. RESULTS: Of 1037 included patients, final eTICI 0-1 was achieved in 46 (4.4%), eTICI 2a in 76 (7.3%), eTICI 2b in 424 (40.9%), eTICI 2c in 284 (27.4%), and eTICI 3 in 207 (20%) patients. The odds for good and excellent clinical outcome gradually increased with improved reperfusion grades (adjOR ranging from 5.7-29.3 and 4.3-17.6) and decreased for sICH and death. No differences in outcomes between first-pass versus multiple-pass eTICI 2c3, eTICI 2b converted-to-eTICI 2c3 versus unchanged eTICI 2b and between sudden versus gradual eTICI 2c3 reperfusion were observed. CONCLUSION: Better reperfusion degrees significantly improved clinical outcomes and reduced mortality, independent of the number of passes and whether eTICI 2c3 was achieved suddenly or gradually.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003223
003      
CZ-PrNML
005      
20250206104159.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/15910199241288874 $2 doi
035    __
$a (PubMed)39397754
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cimflova, Petra $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Department of Radiology, University of Calgary, Calgary, Alberta, Canada $u Department of Medical Imaging, St. Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Diagnostic and Interventional Neuroradiology, Inselspital, University Hospital Bern, Bern, Switzerland $1 https://orcid.org/000000018058383X
245    10
$a Effects of reperfusion grade and reperfusion strategy on the clinical outcome: Insights from ESCAPE-NA1 trial / $c P. Cimflova, JM. Ospel, N. Singh, M. Marko, N. Kashani, A. Mayank, A. Demchuk, B. Menon, AY. Poppe, R. Nogueira, R. McTaggart, JL. Rempel, M. Tymianski, MD. Hill, MA. Almekhlafi, M. Goyal
520    9_
$a BACKGROUND: We evaluated the association of reperfusion quality and different patterns of achieved reperfusion with clinical and radiological outcomes in the ESCAPE NA1 trial. METHODS: Data are from the ESCAPE-NA1 trial. Good clinical outcome [90-day modified Rankin Scale (mRS) 0-2], excellent outcome (90-day mRS0-1), isolated subarachnoid hemorrhage, symptomatic hemorrhage (sICH) on follow-up imaging, and death were compared across different levels of reperfusion defined by expanded Treatment in Cerebral Infarction (eTICI) Scale. Comparisons were also made between patients with (a) first-pass eTICI 2c3 reperfusion vs multiple-pass eTICI 2c3; (b) final eTICI 2b reperfusion vs eTICI 2b converted-to-eTICI 2c3; (c) sudden reperfusion vs gradual reperfusion if >1 pass was required. Multivariable logistic regression was used to test associations of reperfusion grade and clinical outcomes. RESULTS: Of 1037 included patients, final eTICI 0-1 was achieved in 46 (4.4%), eTICI 2a in 76 (7.3%), eTICI 2b in 424 (40.9%), eTICI 2c in 284 (27.4%), and eTICI 3 in 207 (20%) patients. The odds for good and excellent clinical outcome gradually increased with improved reperfusion grades (adjOR ranging from 5.7-29.3 and 4.3-17.6) and decreased for sICH and death. No differences in outcomes between first-pass versus multiple-pass eTICI 2c3, eTICI 2b converted-to-eTICI 2c3 versus unchanged eTICI 2b and between sudden versus gradual eTICI 2c3 reperfusion were observed. CONCLUSION: Better reperfusion degrees significantly improved clinical outcomes and reduced mortality, independent of the number of passes and whether eTICI 2c3 was achieved suddenly or gradually.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a reperfuze $x metody $7 D015424
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a subarachnoidální krvácení $x terapie $x diagnostické zobrazování $x mortalita $7 D013345
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Ospel, Johanna M $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Department of Radiology, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Singh, Nishita $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Department of Internal Medicine-Neurology Division, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
700    1_
$a Marko, Martha $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Department of Neurology, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000290630465
700    1_
$a Kashani, Nima $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Department of Radiology, Rady Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
700    1_
$a Mayank, Arnuv $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Demchuk, Andrew $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Menon, Bijoy $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Poppe, Alexandre Y $u Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
700    1_
$a Nogueira, Raul $u UPMC Stroke Institute, Department of Neurology and Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
700    1_
$a McTaggart, Ryan $u Warren Alpert School of Medicine, Brown University, Providence, RI, USA
700    1_
$a Rempel, Jeremy L $u University of Alberta Hospital, Edmonton, Alberta, Canada
700    1_
$a Tymianski, Michael $u NoNO, Toronto, Ontario, Canada
700    1_
$a Hill, Michael D $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada $u Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Almekhlafi, Mohammed A $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada $u Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
700    1_
$a Goyal, Mayank $u Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada $u Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
773    0_
$w MED00004969 $t Interventional neuroradiology $x 2385-2011 $g Roč. 30, č. 6 (2024), s. 804-811
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39397754 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104155 $b ABA008
999    __
$a ok $b bmc $g 2263150 $s 1239230
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 6 $d 804-811 $e 20241014 $i 2385-2011 $m Interventional neuroradiology $n Interv Neuroradiol $x MED00004969
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options